Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study

  • Epilepsy affects one in every 26 people globally, with as many as one million ED visits, 280 hospital admissions, average hospital stays of 3.6 days, and an aggregate hospital cost of approximately $2.5 billion annually
  • With its severity, prevalence, and overall cost implications, Lexaria is looking to offer an alternative option with its patented DehydraTECH(TM)-CBD
  • Its recent animal seizure study, EPIL-A21-1, showed DehydraTECH-CBD to be equally or even more effective at lower doses than Epidiolex, one of the world’s leading anti-seizure medications and the world’s only commercially approved CBD-powered anti-seizure drug
  • Lexaria looks to build on the findings so far to establish a better understanding of DehydraTECH-CBD for the potential treatment of seizures, a market projected to be valued at $16.6 billion by 2031

According to the Epilepsy Foundation, epilepsy is the fourth most common neurological condition globally, affecting one in every 26 people. About 48 out of every 100,000 people are diagnosed with the condition every year, and as of 2019, it affected approximately 50 million people (https://cnw.fm/OGF3x). With the condition leading to as many as one million emergency department (“ED”) visits and over 280,000 hospital admissions, it attracts average hospital stays of 3.6 days for the patients, with an aggregate hospital cost totaling approximately $2.5 billion annually (https://cnw.fm/Mlp9d).

Given the severity, prevalence, and overall cost implications associated with this condition, there is a dire need for treatment options that are not only effective but also affordable. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, seeks to meet that need with its patented DehydraTECH(TM)-CBD.

In a recent animal seizure study, EPIL-A21-1, designed to establish whether DehydraTECH-CBD could provide similar seizure-inhibiting efficacy at lower doses than that required with Epidiolex, Lexaria’s technology proved to reduce or even eliminate seizure activity in animals. In some cases, it also surpassed the performance of Epidiolex, one of the world’s leading anti-seizure medications. Epidiolex is also the world’s only commercially approved CBD-powered anti-seizure drug. However, in the study, Epidiolex seemed more effective at higher doses compared to DehydraTECH-CBD (https://cnw.fm/RxXp3).

Lexaria is always searching for the lowest possible efficacious dose levels of the drugs it formulates with DehydraTECH in order to minimize adverse side effects.  At lower doses of 50 mg/kg and 75 mg/kg, DehydraTECH proved to be more efficacious than Epidiolex in reducing or eliminating seizure activity, with complete elimination of seizure activity in 66.6% of the animals compared to 50% of Epidiolex-treated animals.

The company looks to build on the findings so far to better understand DehydraTECH-CBD for the potential treatment of seizures, a market, projected to be valued at $16.6 billion by 2031, up from $10.6 billion in 2021.

Lexaria is still considering the optimization of its DehydraTECH-CBD formulation for the reduction or overall elimination of seizure activity and is proud of the progress made thus far. The success of this study adds to the company’s successful streak, with recent positive developments in its hypertension human clinical study program, along with dementia and diabetes studies that kicked off in November.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork.


Select A Month

CanadianCannabisWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 905.674.5977